Cancer Immunotherapy News and Research

RSS

Researchers uncover new way to enhance function of immune cells to combat multiple myeloma

Researchers from Belgium led by Prof. Dirk Elewaut of the VIB-UGent Center for Inflammation Research and the team of Prof. Vanderkerken and Prof. Menu at the Hematology and Immunology lab of the VUB uncovered a new way to enhance the function of a specific type of immune cell that destroys tumors in multiple myeloma, a form of bone marrow cancer considered incurable.

1 Jun 2017

Study describes novel T cell population that recognizes and kills tumor cells

Scientists at the University of Basel in Switzerland have, for the first time, described a new T cell population that can recognize and kill tumor cells. The open access journal eLife has published the results.

23 May 2017

Researchers show how cancer therapy works in different way to destroy tumor cells

Antibodies to the proteins PD-1 and PD-L1 have been shown to fight cancer by unleashing the body's T cells, a type of immune cell.

18 May 2017

Scientists unravel mystery of T cell signaling process vital to immune response

The immune system cells known as T cells play a central role in the body's ability to fight infections and cancer. For decades, however, details of the molecular signaling process that leads to T cell activation have remained a mystery.

16 May 2017

Scientists discover free C3d protein that mitigates tumor-induced immunosuppression

In the body, anti-cancer immunity is immobilized by stealth cancer forces. But a natural de-immobilizer has been identified - and it has a vendetta.

12 May 2017

UAB spinoff develops drug-resistant immunotherapy to combat solid tumors

The University of Alabama at Birmingham and two partner institutions have received a European patent for their novel approach to fighting cancer, an approach that is led by the UAB spinoff biopharmaceutical company Incysus Ltd.

5 May 2017

Mayo Clinic scientists develop novel nanoparticle to shrink tumors, prevent breast cancer recurrence

A Mayo Clinic research team has developed a new type of cancer-fighting nanoparticle aimed at shrinking breast cancer tumors, while also preventing recurrence of the disease.

2 May 2017

Researchers show resident T cells in the skin depend on CD103 molecule for their anti-tumor function

The molecule CD103 is key to the long-term residence of T cells in the skin and to their anti-tumor function, report a team of researchers at the Medical University of South Carolina and the Dartmouth-Hitchcock Norris Cotton Cancer Center In the April 14, 2017, Science Immunology.

28 Apr 2017

UTSW researchers develop new nanoparticle vaccine immunotherapy that targets multiple tumor types

Researchers from UT Southwestern Medical Center have developed a first-of-its-kind nanoparticle vaccine immunotherapy that targets several different cancer types.

24 Apr 2017

Addressing unmet needs in prostate cancer

Prostate cancer is the second most diagnosed cancer globally with over a million men diagnosed worldwide. We are fortunate in that better diagnostic techniques and better awareness means that men are often being diagnosed earlier, which gives them a better chance of being cured.

19 Apr 2017

Nanoparticle-programmed immune cells can slow progression of leukemia in mouse model

Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells -- while the immune cells are still inside the body.

17 Apr 2017

Th17 cell durability offers promise for next-generation adoptive cancer immunotherapy trials

Medical University of South Carolina investigators report that long-term expansion protocols for adoptive cancer immunotherapy do not compromise Th17 cells' effectiveness against large tumors, in the March 9, 2017 issue of JCI Insight.

17 Apr 2017

Patients' immune system profiles could be linked to effectiveness of cancer immunotherapy

Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute.

3 Apr 2017

City of Hope researchers to highlight basic cancer research and population studies at AACR meeting

City of Hope, a world-renowned independent research and cancer and diabetes treatment center, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research at the Walter E. Washington Convention Center in Washington, D.C., April 1 to 5.

28 Mar 2017

Study reveals intriguing crosstalk between metabolism and epigenetics in cancer development

A study published in Briefings in Functional Genomics investigated how epigenetics can modulate human's genetic program -- it can emphasize or silence genes.

24 Mar 2017

Evolution of immuno-oncology

Immuno-oncology did not exist four years ago, it's a term coined by Dr. Axel Hoos, Head of the newly defined immuno-oncology department at GSK. He is also Senior Vice President Therapeutic Area (TA) and Head for Oncology R&D. Previously, it was referred to as cancer immunotherapy, but now it is called immuno-oncology (IO).

13 Mar 2017

Drug could activate innate anti-tumor immunity to eradicate aggressive prostate cancer in mice

Cabozantinib, a drug already used to treat patients with certain types of thyroid or kidney cancer, was able to eradicate invasive prostate cancers in mice by causing tumor cells to secrete factors that entice neutrophils - the first-responders of the immune system - to infiltrate the tumor, where they triggered an immune response that led to tumor clearance.

9 Mar 2017

Research findings show effective way to harness anti-tumor potential of macrophages in cancer therapy

For all the success of a new generation of immunotherapies for cancer, they often leave an entire branch of the immune system's disease-fighting forces untapped.

9 Mar 2017

Scientists devise novel DNA vaccine approach against important cancer antigen targets

Scientists at The Wistar Institute and Inovio Pharmaceuticals, Inc. have devised a novel DNA vaccine approach through molecular design to improve the immune responses elicited against one of the most important cancer antigen targets. Study results were published in the journal Molecular Therapy.

24 Feb 2017

Melanoma patients' immunotherapy response linked to diversity and makeup of gut bacteria

Melanoma patients' response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO-Society for Immunotherapy in Cancer meeting in Orlando.

22 Feb 2017